Toragen
San Diego, United States · Biotechnology, Health Care · 6 employees
Toragen is focused on targeting the root cause of HPV-induced cancers. The company has successfully completed a Phase 1 clinical trial in Stage 4 HPV+ head and neck cancer patients, meeting both primary endpoints of safety and maximum tolerated dose. The trial also demonstrated drug activity in 53% of patients treated.
Funding history
- Funding Round — $12.0M — Sep 2025
- Series seed — $5.4M — Sep 2022
Recent signals
- Sep 30, 2025: Raised $12.0M
- Nov 18, 2024: Launched Toragen Inc. announces positive safety data from its clinical trial of TGN-S11 targeting HPV-associated cancers.
- Sep 30, 2022: Raised $5.4M in Series seed
See plans & pricing → Track Toragen’s funding, hiring, and signals — with verified contacts — on Fundz.